New Liberty has developed novel methods to test new pharmaceuticals' ability to control the Human Immunodeficiency Virus (HIV). Specifically, the Company can assess the efficacy of HIV-1 protease inhibitor candidates. The selfsame methods will prove equally effective in all interaction-based (pathway-based) disease states of crucial importance in biomedicine: Cancer, Alzheimer's Disease, and Metabolism (Diabetes). The Company's drug testing methods are but one part of a larger suite of methods to uniquely assess protein interactions and their modulation by small molecules, such as test pharmaceuticals, abused substances and environmental toxins. New Liberty can offer its unique Methods today on a Fee-For-Service basis.